EAGAN, Minn.--(BUSINESS WIRE)--Biothera will present data today demonstrating a threshold presence of anti-beta glucan antibodies (ABA), IgG and IgM are predictive of binding of the company’s cancer immunotherapy Imprime PGG® to neutrophils and monocytes, which can then recognize and kill cancer cells. The presentation is part of the Keystone Symposia on Inflammation, Infection and Cancer in Whistler, British Columbia, Canada.
Help employers find you! Check out all the jobs and post your resume.
